TABLE 2

ML-145 displays greater potency as an antagonist at human GPR35 than CID-2745687

Human GPR35-β-arrestin-2 interaction assays were conducted by using EC₈₀ amounts of the indicated agonists and varying concentrations of either ML-145 or CID-2745687. In all cases a maximally effective concentration of either antagonist ligand was able to fully reverse the effects of the agonist ligand. Data are means ± S.E.M. from nine independent experiments.